Basis: Current FMP quote-based enterprise value / matching reported total assets. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Assets ratio is 1.06x as of 2026-10-06T21:22:19.684Z.
Calculation as of: 2026-10-06T21:22:19.684Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 610e9c20fcdf10729c15ba1bd616707a7081826ce2aba31979c935d5001cdfd8
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/ASSETS RATIO
1.06x
SECTOR MEDIAN · HEALTHCARE
1.58x
median of 781 covered companies
CURRENT VS SECTOR MEDIAN
-32.91%
vs the sector median at left
Kailera Therapeutics, Inc.
Market Cap
$1.40B
EV/Assets Ratio
1.06x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.40B
EV/Assets Ratio
2.13x
TTM Avg
4.78x
3Y Avg
3.15x
5Y Avg
2.25x
Market Cap
$1.39B
EV/Assets Ratio
1.80x
TTM Avg
1.74x
3Y Avg
1.76x
5Y Avg
1.65x
Market Cap
$1.42B
EV/Assets Ratio
1.98x
TTM Avg
2.62x
3Y Avg
2.52x
5Y Avg
2.49x
Market Cap
$1.37B
EV/Assets Ratio
8.06x
TTM Avg
7.21x
3Y Avg
3.86x
5Y Avg
4.55x
Market Cap
$1.45B
EV/Assets Ratio
1.59x
TTM Avg
1.66x
3Y Avg
1.27x
5Y Avg
1.35x
| NAME | MARKET CAP | EV/ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | $1.40B | 1.06x | N/A | N/A | N/A |
| Taysha Gene Therapies, Inc. (TSHA)vs › | $1.40B | 2.13x | 4.78x | 3.15x | 2.25x |
| Braveheart Bio, Inc. (BRVE)vs › | $1.40B | N/A | N/A | N/A | N/A |
| The Pennant Group, Inc. (PNTG)vs › | $1.39B | 1.80x | 1.74x | 1.76x | 1.65x |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | 4.90x | 4.11x | 1.99x | 1.45x |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.42B | 1.98x | 2.62x | 2.52x | 2.49x |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.37B | 8.06x | 7.21x | 3.86x | 4.55x |
| Certara, Inc. (CERT)vs › | $1.44B | 1.11x | 0.87x | 1.25x | 1.65x |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.45B | 1.59x | 1.66x | 1.27x | 1.35x |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.46B | 2.48x | 3.32x | 2.61x | 2.61x |
EV/Assets compares enterprise value to total assets. It is useful for asset-heavy businesses and for comparing how much the market pays for each dollar of assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
